← All countries · Europe
94%
MCV1
2025 · WHO/UNICEF estimate
94%
DTP3
2025 · WHO/UNICEF estimate
94%
IPV complete
2025 · WHO/UNICEF estimate
90%
HepB3
2025 · WHO/UNICEF estimate
4
Measles cases
2025 reported
10
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 50%1994 · WHO/UNICEF estimate | 50% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 97.8% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 94%2025 · WHO/UNICEF estimate | 93.7% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 97.8% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 94%2025 · WHO/UNICEF estimate | 93.7% | C · weak | |
| MCV1First dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | 93.9% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 83%2025 · WHO/UNICEF estimate | 82.6% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 94%2025 · WHO/UNICEF estimate | 93.9% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 90%2025 · WHO/UNICEF estimate | 90.4% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 93%2025 · WHO/UNICEF estimate | 92.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96.8%2025 · Administrative (country-reported) | 96.8% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 89%2025 · WHO/UNICEF estimate | 88.8% | A · strong | |
| RotaCRotavirus vaccine, complete series | 20%2025 · WHO/UNICEF estimate | — | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 63%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 54%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 38%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 42025 | 0.4per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 12025 | 0.1per 10,000 live births | A · strong | |
| Mumps all countries · vaccine evidence | 32025 | 0.3per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 102025 | 1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 392025 | 3.9per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 102025 | 1per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (108 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B-Y5 | Risk group(s) | Only for neonates that belong to high risk groups |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women with chronic conditions | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPDTaP (acellular) vaccine | 1 | M2 | General/routine | Either DtaP or other combination vaccine (DTaP-IPV, DTaP-IPV-Hib, DTaP-IPV-Hib-HepB) |
| DTAPDTaP (acellular) vaccine | 2 | M4 | General/routine | Either DtaP or other combination vaccine (DTaP-IPV, DTaP-IPV-Hib, DTaP-IPV-Hib-HepB) |
| DTAPDTaP (acellular) vaccine | 3 | M6 | General/routine | Either DtaP or other combination vaccine (DTaP-IPV, DTaP-IPV-Hib, DTaP-IPV-Hib-HepB) |
| DTAPDTaP (acellular) vaccine | 4 | M15-M18 | General/routine | Either DtaP or other combination vaccine (DTaP-IPV, DTaP-IPV-Hib, DTaP-IPV-Hib-HepB) |
| DTAPDTaP (acellular) vaccine | 5 | Y4-Y6 | General/routine | Either DtaP or other combination vaccine (DTaP-IPV, DTaP-IPV-Hib, DTaP-IPV-Hib-HepB) |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | 1st contact | Health workers | High-risk groups, pregnant, HCW |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | 1st contact | Pregnant women | High-risk groups, pregnant, HCW |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | >=Y18 | Risk group(s) | High-risk groups, pregnant, HCW |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6-M12 | Health workers | High-risk groups, pregnant, HCW |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6-M12 | Pregnant women | High-risk groups, pregnant, HCW |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6-M12 | Risk group(s) | High-risk groups, pregnant, HCW |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Y2-Y6 | General/routine | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | +M6 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y18 | Risk group(s) | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Travellers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Health workers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Travellers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Travellers | High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | M2 | General/routine | HepB is given to all infants either at M2 or at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | HepB is given to all infants either at M2 or at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M4 | General/routine | HepB is given to all infants either at M2 or at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6-M18 | General/routine | HepB is given to all infants either at M2 or at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M2 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | For high-risk groups | |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M4 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 3 | M6 | General/routine | |
| HIBHib (Haemophilus influenzae type B) vaccine | 4 | M15-M18 | General/routine | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y9-Y11 | HPV administered to females and males | Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 2 doses (0M, +(6M-12M). In high risk groups 3 doses (0, M1-M2, M6) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y18-Y45 | Risk group(s) | Females and males belonging to high-risk groups between 18-45 years, 2 doses (0,+M6) or 3 doses (o, M1=M2, M6) in HIV and immunosupression. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6-M12 | HPV administered to females and males | Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 2 doses (0M, +(6M-12M). In high risk groups 3 doses (0, M1-M2, M6) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M1 | Risk group(s) | Females and males belonging to high-risk groups between 18-45 years, 2 doses (0,+M6) or 3 doses (o, M1=M2, M6) in HIV and immunosupression. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | Risk group(s) | Females and males belonging to high-risk groups between 18-45 years, 2 doses (0,+M6) or 3 doses (o, M1=M2, M6) in HIV and immunosupression. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y5 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6-M18 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 4 | Y4-Y6 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y11-Y12 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | For high-risk groups, the dose schedule depends on the groups | |
| MEN_BMeningococcal B vaccine | 1 | M2 | General/routine | MenB-4C |
| MEN_BMeningococcal B vaccine | 1 | Risk group(s) | For high-risk groups, the dose schedule depends on the vaccine | |
| MEN_BMeningococcal B vaccine | 2 | M4 | General/routine | MenB-4C |
| MEN_BMeningococcal B vaccine | 3 | M12-M15 | General/routine | MenB-4C |
| MEN_C_CONJMeningococcal C conjugate vaccine | 1 | M10 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12-M15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | 1st contact | Health workers | susceptible persons born after 1970 and high risk groups, HCW |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | 1st contact | Risk group(s) | susceptible persons born after 1970 and high risk groups, HCW |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M24-M35 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +M1 | Health workers | susceptible persons born after 1970 and high risk groups, HCW |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | +M1 | Risk group(s) | susceptible persons born after 1970 and high risk groups, HCW |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M12-M15 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M24-M35 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | >=Y65 | Adults | Y19-Y64 high risk groups, and all adults ≥Y65 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | PCV15 or PCV20 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | Y19-Y64 | Risk group(s) | Y19-Y64 high risk groups, and all adults ≥Y65 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M4 | General/routine | PCV15 or PCV20 |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M12 | General/routine | PCV15 or PCV20 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | PCV15 or PCV20 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M4 | General/routine | PCV15 or PCV20 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | PCV15 or PCV20 |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | RV1 |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | RV1 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | RV5 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | RV5 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | RV5 |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Adults | Pregnat > or equal 18Y, 60-74Y high risk and > or equal 75Y | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnat > or equal 18Y, 60-74Y high risk and > or equal 75Y | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Risk group(s) | Pregnat > or equal 18Y, 60-74Y high risk and > or equal 75Y | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B | General/routine | Newborns |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | infants <6 months, high risk, born from unvaccinated mothers during pregnancy; Infants 6m- <24 m, high risk group, born from unvaccinated mothers during pregnancy | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Y18-Y25 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 2 | +Y10 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 3 | +Y10 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 4 | +Y10 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | +Y10 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | +Y10 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y11-Y12 | General/routine | Y11-Y12 (Tdap/Tdap-IPV) |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 1 | Y18-Y25 | Adults | Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 6 | Y11-Y12 | General/routine | Y11-Y12 (Tdap/Tdap-IPV) |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +Y10 | Adults | Td/Tdap every 10Y |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +Y10 | Adults | Td/Tdap every 10Y |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y10 | Adults | Td/Tdap every 10Y |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y10 | Adults | Td/Tdap every 10Y |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | +Y10 | Adults | Td/Tdap every 10Y |
| VARICELLAVaricella vaccine | 1 | M12-M15 | General/routine | |
| VARICELLAVaricella vaccine | 1 | 1st contact | Health workers | susceptible persons born after 1970 and high risk groups, HCW |
| VARICELLAVaricella vaccine | 1 | 1st contact | Risk group(s) | susceptible persons born after 1970 and high risk groups, HCW |
| VARICELLAVaricella vaccine | 2 | M24-M35 | General/routine | |
| VARICELLAVaricella vaccine | 2 | +M1 | Health workers | susceptible persons born after 1970 and high risk groups, HCW |
| VARICELLAVaricella vaccine | 2 | +M1 | Risk group(s) | susceptible persons born after 1970 and high risk groups, HCW |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y60 | Adults | adults ≥18Y with immunosupression, and all adults ≥Y60 |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y18 | Risk group(s) | adults ≥18Y with immunosupression, and all adults ≥Y60 |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2-M6 | Adults | adults ≥18Y with immunosupression, and all adults ≥Y60 |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2-M6 | Risk group(s) | adults ≥18Y with immunosupression, and all adults ≥Y60 |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.